General Information of DTT (ID: TTXWASR)

DTT Name Intestinal maltase-glucoamylase (MGAM) DTT Info
Gene Name MGAM

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
4 Approved Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Acarbose DMRM3AW Diabetic complication 5A2Y Approved [1]
Miglitol DMXBQAM Diabetic complication 5A2Y Approved [2]
Rh-alphaglucosidase DMNF0G8 Pompe disease 5C51.3 Approved [3]
Voglibose DMUBP9O Diabetic complication 5A2Y Approved [4]
------------------------------------------------------------------------------------
7 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Alpha-glucosidase DM2RTGP Muscle disease FB3Z Phase 3 [5]
Deoxynojirimycin DM2ATZB Pompe disease 5C51.3 Phase 3 [6]
PAZ-320 DMU0812 Type-2 diabetes 5A11 Phase 2 [7]
SC-49483 DM180VX Acquired immune deficiency syndrome 1C62.3 Phase 2 [8]
Celgosivir DMD1V7I Dengue fever 1D2Z Phase 1/2 [9]
Maltose DMH0ROP N. A. N. A. Phase 1/2 [10]
SALACINOL DMVKQT8 N. A. N. A. Phase 1/2 [11]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 Clinical Trial Drug(s)
1 Discontinued Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
A-76202M DMRHEWX Acquired immune deficiency syndrome 1C62.3 Terminated [12]
------------------------------------------------------------------------------------
14 Investigative Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
1,4-dideoxy-1,4-imino-D-arabinito DMB5VQK Discovery agent N.A. Investigative [13]
2,5-Dideoxy-2,5-imino-D-mannitol DMGQVF5 Discovery agent N.A. Investigative [13]
2-Aminomethyl-pyrrolidine-3,4-diol DMAN8EH Discovery agent N.A. Investigative [14]
2-Cyclopentylaminomethyl-pyrrolidine-3,4-diol DMS947W Discovery agent N.A. Investigative [14]
3-(4-(4-hydroxyphenyl)phthalazin-1-ylamino)phenol DM1GVE8 Discovery agent N.A. Investigative [15]
4'-(p-toluenesulfonamide)-3,4-dihydroxy chalcone DM8M0N9 Discovery agent N.A. Investigative [16]
BMN-103 DMYWEO6 Pompe disease 5C51.3 Investigative [5]
De-O-sulfonated kotalanol DMNWRV9 Discovery agent N.A. Investigative [11]
Double Oxidized Cysteine DM6TU84 Discovery agent N.A. Investigative [17]
GSC-1 DMTKGA3 Hyperglycemia MA18.0 Investigative [5]
Imino sugars DMSINGH Dengue fever 1D2Z Investigative [5]
KOTALANOL DMT1H9Z Discovery agent N.A. Investigative [11]
Nicotinamide-Adenine-Dinucleotide DM9LRKB N. A. N. A. Investigative [17]
PONKORANOL DMGRPK8 Discovery agent N.A. Investigative [18]
------------------------------------------------------------------------------------
⏷ Show the Full List of 14 Investigative Drug(s)
Molecule Interaction Atlas

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
2 Drug therapy of postprandial hyperglycaemia. Drugs. 1999 Jan;57(1):19-29.
3 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
4 Effects of changeover from voglibose to acarbose on postprandial triglycerides in type 2 diabetes mellitus patients. Adv Ther. 2009 Jun;26(6):660-6.
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2627).
6 Nitrogen-in-the-ring pyranoses and furanoses: structural basis of inhibition of mammalian glycosidases. J Med Chem. 1994 Oct 28;37(22):3701-6.
7 Treatment With Novel Galactomannan Derivative Reduces 2-Hour Postprandial Glucose Excursions in Individuals With Type 2 Diabetes Treated With Oral Medications and/or Insulin. J Diabetes Sci Technol. 2014 September; 8(5): 1018-1022.
8 Pathology of perbutylated-N-butyl-1-deoxynojiromycin (an alpha-glucosidase-1 inhibitor) in Sprague-Dawley rats. Toxicol Pathol. 1996 Sep-Oct;24(5):531-8.
9 Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection.Curr Opin Investig Drugs.2009 Aug;10(8):860-70.
10 DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
11 Probing the active-site requirements of human intestinal N-terminal maltase-glucoamylase: Synthesis and enzyme inhibitory activities of a six-membe... Bioorg Med Chem. 2010 Nov 15;18(22):7794-8.
12 Synthesis and biological activity of 4',8-dihydroxyisoflavon-7-yl D-hexopyranosides. Carbohydr Res. 2001 Oct 15;335(4):283-9.
13 New sugar-mimic alkaloids from the pods of Angylocalyx pynaertii. J Nat Prod. 2002 Feb;65(2):198-202.
14 Derivatives of (2R,3R,4S)-2-aminomethylpyrrolidine-3,4-diol are selective alpha-mannosidase inhibitors. Bioorg Med Chem Lett. 2001 Sep 17;11(18):2489-93.
15 Discovery of novel alpha-glucosidase inhibitors based on the virtual screening with the homology-modeled protein structure. Bioorg Med Chem. 2008 Jan 1;16(1):284-92.
16 Sulfonamide chalcone as a new class of alpha-glucosidase inhibitors. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5514-6.
17 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
18 Probing the active-site requirements of human intestinal N-terminal maltase glucoamylase: the effect of replacing the sulfate moiety by a methyl et... Bioorg Med Chem Lett. 2010 Oct 1;20(19):5686-9.